Vasculitis & polymyalgia rheumatica
Pentraxin-3 – a potential biomarker in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Authors' conclusion
Plasma and urinary PTX3 seem to reflect disease activity in AAV better than the commonly used CRP.
Study context
- Population
- Newly diagnosed or relapsing AAV patients, with healthy controlsurinary PTX3 in 34 patients
- Participants
- 79 vs 23
- Exposure
- Plasma PTX3 at baseline vs 6-month follow-up in AAV; healthy controls
- AAVn = 79
- Healthy controlsn = 23reference
- Outcome
- PTX3 as a potential biomarker of inflammatory activity in AAV (plasma PTX3 levels)
- Follow-up
- Baseline and 6 month
Methodological detailshealthy controls
- Healthy controls
Main finding
As reported in the abstract
Plasma PTX3 levels, baseline vs 6 months
P < 0.001
Observational data: associations, not effects.
Further findings
Correlation of PTX3 with Birmingham Vasculitis Activity Score (BVAS) at baseline
- Plasma PTX3 vs BVAS, ρ (p < 0.001)
- 0.45
- Urinary PTX3 vs BVAS, ρ (p = 0.008)
- 0.49
Other correlations and kidney involvement · baseline
- Plasma and urinary PTX3 significantly correlated with eGFR and albuminuria
- No correlation between plasma and urinary PTX3
- Plasma and urinary PTX3 significantly higher in patients with kidney involvement
- PTX3 did not correlate with C-reactive protein (CRP); no correlation between CRP and BVAS at baseline
Original publication
Pentraxin-3 – a potential biomarker in ANCA-associated vasculitis. Scand J Rheumatol. Published 6 April 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →